|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 601 PENNSYLVANIA AVENUE, NW, #740 |
Address2 | |
City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 31348-12
|
||||||||
|
6. House ID# 340040000
|
TYPE OF REPORT | 8. Year | 2010 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Brenda Palmer, Chief Financial Officer |
Date | 07/20/2010 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Issues related to Medicare/Medicaid drug coverage including pharmacy payments (average manufacturer price), reimbursements, competition and plan administration, electronic prescribing, chronic care and PBM disclosure.
Health reform proposals impacting prescription drug coverage including formulary requirements, generic drug co-payments, direct negotiation, Medicaide rebate changes, applying Medicaid rebates in Medicare, closure of Part D coverage gap, retiree drug subsidy,
funding/revenues for Health Care Reform, H.R. 3200, S1679 America's Health Future Act, H.R. 3950 Patient Protection and Affordable Care Act.
H.R. 4752 - Medicare Prescription Drug Price Negotiation Act of 2010
H.R. 4872 - Health Care and Education Reconciliation Act of 2010
H.R. 4199 - Patient Health and Real Medication Access Cost Savings Act of 2009
H.R. 4813 - To provide for insurance reform (including health insurance reform), amend Title XVIII of the Social Security Act to reform Medicare Advantage and reduce disparities in the Medicare Program, regulate the importation of prescription drugs, and for other purposes.
17. House(s) of Congress and Federal agencies Check if None
Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mark |
Merritt |
|
|
|
Jonathan |
Heafitz |
|
|
|
Kristin |
Bass |
|
|
|
Jerry |
Steffl |
|
|
|
Greg |
Johnson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Establishing a regulatory approval pathway for biogeneric drugs - H.R. 1427/S726 - Promoting Innovation and Access to Life Saving Medicine Act and H.R. 1548 - Pathway for Biosimilars Act
Items related to the application of drug benenfits to public plans and health exchange, including PBM disclosure in H.R. 3000, S169 - America's Health Future Act, H.R. 3962, H.R. 3950 - Patient Protection and Affordable Care Act.
H.R. 4872 - Health Care and Education Reconciliation Act of 2010
H.R. 4199 - Patient Health and Real Medication Access Cost Savings Act of 2009
H.R. 4813 - To provide for insurance reform (including health insurance reform) amend Title XVIII of the Social Security Act to reform medicare Advantage and reduce disparities in the Medicare Program, regulate the importation of prescription drugs, and for other purposes.
H.R. 4489 - FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mark |
Merritt |
|
|
|
Jonathan |
Heafitz |
|
|
|
Kristin |
Bass |
|
|
|
Jerry |
Steffl |
|
|
|
Greg |
Johnson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
H.R. 1204 - Community Pharmacy Fairness Act, Electronic Prescribing, Mail Order and Pharmacy Chronic Care Management
H.R. 1706, S369 relating to settlement payments between brand and generic manufacturers, issues related to oversight of pharmacy benefits for federal employee health benefits program, items related to the application of drug benefits to public plans and health exchange, including PBM disclosure in H.R. 3200, S11679 America's Health Future Act, issues related to generic dispensing and
study of the impact of state 'carve-out" laws on generic utilization.
H.R. 4199 - Patients Health and Real Medication Access Cost Savings Act.
H.R. 5234 - PBM Audit Reform and Transparency Act
H.R. 4872 - Health Care and Education and Reconciliation Act of 2010
H.R. 4813 - To provide for insurance reform (including health insurance reform) amend Title XVIII of the Social Security Act to reform Medicare Advantage and reduce disparities in the Medicare Program, regulate the importation of prescription drugs, and for other purposes.
H.R. 4489 - FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act
H.R. 3950 - Patient Protection and Affordable Care Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Federal Election Commission (FEC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mark |
Merritt |
|
|
|
Jonathan |
Heafitz |
|
|
|
Kristin |
Bass |
|
|
|
Jerry |
Steffl |
|
|
|
Greg |
Johnson |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |